These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15215875)

  • 21. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
    Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
    Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.
    Kotake S; Udagawa N; Hakoda M; Mogi M; Yano K; Tsuda E; Takahashi K; Furuya T; Ishiyama S; Kim KJ; Saito S; Nishikawa T; Takahashi N; Togari A; Tomatsu T; Suda T; Kamatani N
    Arthritis Rheum; 2001 May; 44(5):1003-12. PubMed ID: 11352231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
    Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
    Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
    Terpos E; Szydlo R; Apperley JF; Hatjiharissi E; Politou M; Meletis J; Viniou N; Yataganas X; Goldman JM; Rahemtulla A
    Blood; 2003 Aug; 102(3):1064-9. PubMed ID: 12689925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
    Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ
    J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule.
    Zehnder AF; Kristiansen AG; Adams JC; Merchant SN; McKenna MJ
    Laryngoscope; 2005 Jan; 115(1):172-7. PubMed ID: 15630389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
    Buxton EC; Yao W; Lane NE
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3332-6. PubMed ID: 15240611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
    Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
    Dovio A; Data V; Angeli A
    J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
    Terpos E; Christoulas D; Kastritis E; Katodritou E; Papatheodorou A; Pouli A; Kyrtsonis MC; Michalis E; Papanikolaou X; Gkotzamanidou M; Koulieris E; Gavriatopoulou M; Zervas K; Dimopoulos MA;
    Am J Hematol; 2014 Jan; 89(1):34-40. PubMed ID: 23983166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease].
    Xu DR; Su C; Zou WY; Xu HR; Huang S; Li J; Luo SK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):376-80. PubMed ID: 20416172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma.
    Terpos E; Samarkos M; Meletis C; Apostolidou E; Tsironi M; Korovesis K; Mavrogianni D; Viniou N; Meletis J
    Int J Hematol; 2003 Nov; 78(4):344-8. PubMed ID: 14686493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.